¼¼°èÀÇ °¨¸¶ ³ªÀÌÇÁ ½ÃÀå
Gamma Knife
»óǰÄÚµå : 1768522
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 189 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,225,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,675,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °¨¸¶ ³ªÀÌÇÁ ½ÃÀåÀº 2030³â±îÁö 4¾ï 390¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3¾ï 1,080¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ °¨¸¶ ³ªÀÌÇÁ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 4¾ï 390¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¾Ç¼º Á¾¾çÀº CAGR 4.7%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 2,110¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ç¼º Á¾¾ç ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8,220¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °¨¸¶ ³ªÀÌÇÁ ½ÃÀåÀº 2024³â¿¡ 8,220¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 8,730¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.9%¿Í 3.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °¨¸¶ ³ªÀÌÇÁ ½ÃÀå - Á¤ÀÇ, ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°¨¸¶³ªÀÌÇÁ¶õ ¹«¾ùÀ̸ç, ¿Ö Çö´ë ½Å°æ¿Ü°ú¿¡¼­ Áß¿äÇѰ¡?

°¨¸¶³ªÀÌÇÁ´Â Á¤À§Àû ¹æ»ç¼± ¼ö¼ú(SRS)ÀÇ ÀÏÁ¾À¸·Î ħ½ÀÀû ¼ö¼ú ¾øÀÌ ³úÁ¾¾ç, Ç÷°ü ±âÇü, ±âŸ ½Å°æÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ±×·±µ¥ ¿Ö °¨¸¶³ªÀÌÇÁ°¡ ½Å°æ¿Ü°ú¿¡¼­ ȹ±âÀûÀÎ Ä¡·á¹ýÀ¸·Î ¿©°ÜÁö´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡? ±âÁ¸ ¼ö¼ú°ú ´Þ¸® °¨¸¶³ªÀÌÇÁ´Â °¨¸¶¼± ÁýÁß ºöÀ» »ç¿ëÇÏ¿© ³úÀÇ ºñÁ¤»óÀûÀÎ Á¶Á÷À» Á¤È®ÇÏ°Ô Á¶ÁØÇÏ¿© ÁÖº¯ °Ç°­ÇÑ Á¶Á÷À» ¼Õ»ó½ÃŰÁö ¾Ê°í °í¼±·®ÀÇ ¹æ»ç¼±À» Á¶»çÇß½À´Ï´Ù. ÀÌ ºñħ½ÀÀû ¼ö¼úÀº Á¤È®¼º, È¿°ú, ȸº¹ ½Ã°£ ´ÜÃàÀ¸·Î À¯¸íÇÏ¸ç ³ú ÀüÀÌ, µ¿Á¤¸Æ ±âÇü(AVM), »ïÂ÷ ½Å°æÅë, ÀϺΠ¾ç¼º ¹× ¾Ç¼º ³úÁ¾¾ç µîÀÇ È¯ÀÚ¿¡°Ô ¼±È£µÇ´Â ºñħ½ÀÀû ¼ö¼úÀÔ´Ï´Ù. °¨¸¶³ªÀÌÇÁ´Â ¹°¸®Àû Àý°³°¡ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ °¨¿°, ÃâÇ÷, Àå±â ȸº¹°ú °°Àº ±âÁ¸ ³ú ¼ö¼úÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. º¸´Ù ÃÖ¼Ò Ä§½ÀÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó °¨¸¶³ªÀÌÇÁ ±â¼úÀº º¹ÀâÇÑ ³ú ÁúȯÀ» Á¤È®Çϰí ÃÖ¼ÒÇÑÀÇ ºÎÀÛ¿ëÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ Çö´ë ½Å°æ¿Ü°ú¿¡¼­ Á¡Á¡ ´õ Á߿伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº °¨¸¶³ªÀÌÇÁ ½ÃÀåÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

±â¼ú Çõ½ÅÀº °¨¸¶³ªÀÌÇÁ ½Ã½ºÅÛÀÇ ¹ßÀü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÇÑ °¡Áö Áß¿äÇÑ ¹ßÀüÀº °¨¸¶³ªÀÌÇÁ ½Ã½ºÅÛ°ú MRI ¹× CT ½ºÄµ°ú °°Àº ÷´Ü ¿µ»ó ±â¼úÀ» °¨¸¶³ªÀÌÇÁ ½Ã½ºÅÛ°ú ÅëÇÕÇÏ¿© Ä¡·á °èȹ°ú Á¤È®µµ¸¦ Çâ»ó½ÃŲ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿µ»ó ±â¼úÀ» ÅëÇØ ³ú º´º¯ÀÇ À§Ä¡¸¦ º¸´Ù Á¤È®ÇÏ°Ô ÆÄ¾ÇÇÒ ¼ö ÀÖ°í, ¹æ»ç¼±À» ÇÊ¿äÇÑ °÷¿¡ Á¤È®ÇÏ°Ô Á¶»çÇÏ¿© °Ç°­ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Ç½Ã°£ ¿µ»óó¸®¿Í 3D Ä¡·á°èȹ ¼ÒÇÁÆ®¿þ¾îÀÇ µµÀÔÀ¸·Î ¼±·® Á¶»çÀÇ Á¤È®µµ°¡ Çâ»óµÇ¾î ³ú ÀüÀÌ ¹× AVM°ú °°Àº Áúȯ¿¡ ´ëÇØ º¸´Ù Ç¥ÀûÈ­µÈ Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ±â¼ú Çõ½ÅÀº °¨¸¶³ªÀÌÇÁ ±â¼ú ÀÚüÀÇ ÁøÈ­ÀÔ´Ï´Ù. °¨¸¶³ªÀÌÇÁ ¾ÆÀÌÄܰú °°Àº °¨¸¶³ªÀÌÇÁ ½Ã½ºÅÛÀÇ ÃֽйöÀüÀº ÷´Ü ¸ð¼Ç Æ®·¡Å· ¹× °íÁ¤ ½Ã½ºÅÛÀ» žÀçÇÏ¿© ÇÁ·¹ÀÓ¸®½º Ä¡·á°¡ °¡´ÉÇÕ´Ï´Ù. À̸¦ ÅëÇØ ȯÀÚÀÇ ºÒÆíÇÔÀ» ÁÙÀ̰í Ä¡·áÇÒ ¼ö ÀÖ´Â º´ÅÂÀÇ ÆøÀ» ³ÐÇôÁÝ´Ï´Ù. ¶ÇÇÑ »õ·Î¿î ½Ã½ºÅÛÀº ºÐÇÒ Ä¡·á°¡ °¡´ÉÇÏ¿© Çʿ信 µû¶ó ¿©·¯ ¹ø ³ª´©¾î ¹æ»ç¼±À» Á¶»çÇÒ ¼ö ÀÖÀ¸¸ç, ´õ Å« º´º¯À̳ª º¹ÀâÇÑ º´º¯ÀÇ Ä¡·á¿¡µµ À¯¿¬ÇÏ°Ô ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀ¸·Î °¨¸¶³ªÀÌÇÁ Ä¡·á´Â ´õ¿í ¾ÈÀüÇϰí, Æí¾ÈÇϰí, È¿°úÀûÀ̸ç, ÀÇ·áÁøÀÌ º¸´Ù ±¤¹üÀ§ÇÑ ½Å°æÁúȯ¿¡ ´ëÇÑ ¹æ»ç¼± ¼ö¼úÀÇ »ç¿ëÀ» È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

±ÔÁ¦¿Í ÇコÄÉ¾î µ¿ÇâÀÌ °¨¸¶³ªÀÌÇÁ ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

°¨¸¶³ªÀÌÇÁ ½ÃÀå Çü¼º¿¡ ÀÖÀ¸¸ç, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ÇコÄÉ¾î µ¿ÇâÀº ¾î¶² ¿ªÇÒÀ» Çϰí Àִ°¡? ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú À¯·´ÀǾàǰû(EMA)°ú °°Àº ±ÔÁ¦±â°üÀº °¨¸¶³ªÀÌÇÁ ±â¼úÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀº °¨¸¶³ªÀÌÇÁ ½Ã½ºÅÛ°ú °°Àº ÀÇ·á±â±âÀÇ ½ÂÀÎ ¹× »ç¿ëÀ» À¯µµÇÏ¿© ÀÌ·¯ÇÑ Ä¡·á°¡ ¾ÈÀü ¿ä°ÇÀ» ÃæÁ·Çϰí ÀϰüµÈ °íǰÁú Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ¹æ»ç¼± ¾ÈÀü Ç¥ÁØÀ» ÁؼöÇØ¾ß Çϸç, ÀÌ´Â Àü ¼¼°è¿¡¼­ Á¤À§Àû ¹æ»ç¼± ¼ö¼úÀÇ »ç¿ëÀÌ È®´ëµÊ¿¡ µû¶ó Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

°¡Ä¡ ±â¹Ý ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ °¨¸¶³ªÀÌÇÁ ±â¼ú äÅÿ¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ °á°ú ±â¹Ý ¸ðµ¨·Î ÀüȯµÊ¿¡ µû¶ó °¨¸¶³ªÀÌÇÁ¿Í °°ÀÌ Á¤È®µµ°¡ ³ô°í ºÎÀÛ¿ëÀÌ ÀûÀ¸¸ç ȸº¹ ½Ã°£ÀÌ ÂªÀº Ä¡·á¹ýÀº ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡°Ô ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡¿À°í ÀÖ½À´Ï´Ù. ÀÔ¿ø ±â°£°ú ÀçȰ ±â°£ÀÌ ±æ¾îÁö´Â ±âÁ¸ °³º¹ ¼ö¼ú¿¡ ºñÇØ ºñħ½ÀÀû ¼ö¼úÀÇ ºñ¿ë È¿À²¼ºÀÌ ³ô±â ¶§¹®¿¡ Á¡Á¡ ´õ ¸¹Àº º´¿ø ¹× Ŭ¸®´ÐÀÌ °¨¸¶³ªÀÌÇÁ ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Àü ¼¼°è¿¡¼­ Á¤À§Àû ¹æ»ç¼± ¼ö¼ú¼¾ÅͰ¡ È®´ëµÇ°í ÀÖÀ¸¸ç, ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ¶óƾ¾Æ¸Þ¸®Ä« µîÀÇ Áö¿ª¿¡¼­ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ Àü ¼¼°è¿¡¼­ ¾Ï ¹ßº´·ü Áõ°¡, ƯÈ÷ ³ú ÀüÀÌ Áõ°¡·Î ÀÎÇØ °¨¸¶³ªÀÌÇÁ¿Í °°Àº ÷´Ü ¹æ»ç¼± ¼ö¼ú Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ¹× ÇコÄÉ¾î µ¿ÇâÀº °¨¸¶³ªÀÌÇÁ°¡ º¹ÀâÇÑ ³ú ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ¾ÈÀüÇϰí È¿°úÀûÀÌ¸ç °æÁ¦ÀûÀ¸·Î ½ÇÇà °¡´ÉÇÑ ¼±ÅÃÀÌ µÉ ¼ö ÀÖµµ·Ï º¸ÀåÇÏ¸ç ½ÃÀåÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

°¨¸¶³ªÀÌÇÁ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº?

°¨¸¶³ªÀÌÇÁ ½ÃÀåÀÇ ¼ºÀåÀº ³ú ÁúȯÀÇ À¯º´·ü Áõ°¡, ¹æ»ç¼± ¼ö¼ú ±â¼úÀÇ ¹ßÀü, ÃÖ¼Òħ½ÀÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ³úÁ¾¾ç, Ç÷°ü ±âÇü, ½Å°æ Àå¾ÖÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ Á¤¹ÐÇϰí È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °¨¸¶³ªÀÌÇÁ ¹æ»ç¼± ¼ö¼úÀº ÃÖ¼ÒÇÑÀÇ À§ÇèÀ¸·Î ÀÌ·¯ÇÑ ÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î ³Î¸® ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ±âÁ¸ ¼ö¼úÀÌ ÀûÇÕÇÏÁö ¾ÊÀº ȯÀڵ鿡°Ô ¼±È£µÇ´Â Ä¡·á¹ýÀÔ´Ï´Ù. °¨¸¶³ªÀÌÇÁ Ä¡·áÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½ÃŲ ¿µ»ó ¹× ¹æ»ç¼± ±â¼úÀÇ ¹ßÀüÀº °¨¸¶³ªÀÌÇÁ Ä¡·áÀÇ Å« ¿øµ¿·ÂÀÌ µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ ÀÇ·áÁøÀº ´õ º¹ÀâÇÑ È¯ÀÚ¸¦ Ä¡·áÇϰí, ȯÀÚ °á°ú¸¦ °³¼±Çϸç, ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ °í·ÉÈ­ »çȸ´Â °¨¸¶³ªÀÌÇÁ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °í·É ȯÀÚ´Â ³ú ÁúȯÀÇ À§ÇèÀÌ ³ôÀº °æ¿ì°¡ ¸¹¾Æ ºñħ½ÀÀû Ä¡·á¹ýÀ» ã´Â °æÇâÀÌ ³ô±â ¶§¹®ÀÔ´Ï´Ù.

¶ÇÇÑ È¯ÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ºü¸¥ ȸº¹°ú ÇÕº´ÁõÀÌ ÀûÀº Ä¡·á¸¦ ¿øÇϹǷΠ¿Ü·¡ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °¨¸¶³ªÀÌÇÁ Ä¡·á´Â ÀϹÝÀûÀ¸·Î ÇÏ·í¹ãÀÇ ÀÔ¿øÀÌ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ ¿Ü·¡ ȯÀڵ鿡°Ô ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. °¨¸¶³ªÀÌÇÁ ¼¾ÅͰ¡ Àü ¼¼°è¿¡¼­, ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ Á¡Á¡ ´õ ¸¹Àº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀÌ ÀÌ Ã·´Ü ±â¼ú¿¡ ÅõÀÚÇϸ鼭 ½ÃÀå È®´ë¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±â¼ú ¹ßÀü, ½Å°æÁúȯÀÇ ºÎ´ã Áõ°¡ µîÀÇ ¿äÀÎÀÌ °áÇÕµÇ¾î °¨¸¶ ³ªÀÌÇÁ ¼¼°è ½ÃÀåÀº °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖÀ¸¸ç, °¨¸¶³ªÀÌÇÁ´Â ½Å°æ¿Ü°úÀÇ ¹Ì·¡¿¡¼­ Áß¿äÇÑ Åø·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÀûÀÀÁõ(¾Ç¼º Á¾¾ç, ¾ç¼º Á¾¾ç, Ç÷°ü Àå¾Ö, ±â´É Àå¾Ö, ¾ÈÁúȯ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gamma Knife Market to Reach US$403.9 Million by 2030

The global market for Gamma Knife estimated at US$310.8 Million in the year 2024, is expected to reach US$403.9 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Malignant Tumors, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$221.1 Million by the end of the analysis period. Growth in the Benign Tumors segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$82.2 Million While China is Forecast to Grow at 6.9% CAGR

The Gamma Knife market in the U.S. is estimated at US$82.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$87.3 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Gamma Knife Market - Definition, Key Trends & Drivers Summarized

What Is Gamma Knife and Why Is It Important in Modern Neurosurgery?

Gamma Knife is a form of stereotactic radiosurgery (SRS) used to treat brain tumors, vascular malformations, and other neurological conditions without invasive surgery. But why is Gamma Knife considered a breakthrough in neurosurgery? Unlike traditional surgery, Gamma Knife uses focused beams of gamma radiation to precisely target abnormal tissue in the brain, delivering high doses of radiation without harming surrounding healthy tissue. This non-invasive procedure is known for its accuracy, effectiveness, and reduced recovery time, making it a preferred option for patients with conditions like brain metastases, arteriovenous malformations (AVMs), trigeminal neuralgia, and certain types of benign and malignant brain tumors. Since Gamma Knife does not require physical incisions, the risks associated with traditional brain surgery-such as infection, bleeding, and extended recovery-are minimized. As demand for less invasive treatments grows, Gamma Knife technology has become increasingly important in modern neurosurgery for its ability to treat complex brain conditions with precision and minimal side effects.

How Are Technological Advancements Shaping the Gamma Knife Market?

Technological innovations are playing a key role in advancing Gamma Knife systems. But how are these advancements improving the effectiveness and safety of the procedure? One major development is the integration of advanced imaging technologies, such as MRI and CT scans, with Gamma Knife systems to enhance treatment planning and accuracy. These imaging techniques allow for more precise localization of brain lesions, ensuring that radiation is delivered exactly where it is needed, minimizing damage to healthy tissue. The incorporation of real-time imaging and 3D treatment planning software has also improved the precision of dose delivery, enabling more targeted treatments for conditions like brain metastases and AVMs.

Another key innovation is the evolution of the Gamma Knife technology itself. The latest versions of Gamma Knife systems, such as the Gamma Knife Icon, feature advanced motion tracking and immobilization systems, allowing for frameless treatments. This reduces patient discomfort and expands the range of treatable conditions. Moreover, new systems offer the ability to deliver fractionated treatments, meaning that radiation can be delivered over multiple sessions if needed, providing more flexibility for treating larger or more complex lesions.

These technological advancements are making Gamma Knife treatments safer, more comfortable, and more effective, helping healthcare providers expand the use of radiosurgery for a broader range of neurological conditions.

How Are Regulations and Healthcare Trends Impacting the Gamma Knife Market?

What role do regulatory frameworks and healthcare trends play in shaping the Gamma Knife market? Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a critical role in ensuring the safety and efficacy of Gamma Knife technology. Strict regulatory standards guide the approval and use of medical devices like Gamma Knife systems, ensuring that these treatments meet safety requirements and deliver consistent, high-quality care. Additionally, healthcare providers must comply with radiation safety standards, which are becoming increasingly important as the use of stereotactic radiosurgery expands globally.

The growing trend toward value-based healthcare is also influencing the adoption of Gamma Knife technology. As healthcare systems shift toward outcomes-based models, treatments that offer high precision, reduced side effects, and shorter recovery times-such as Gamma Knife-are becoming more attractive to both patients and providers. The cost-effectiveness of non-invasive procedures, compared to traditional open surgery with longer hospitalization and rehabilitation periods, is encouraging more hospitals and clinics to invest in Gamma Knife technology. Moreover, the rising demand for minimally invasive treatments is driving the expansion of stereotactic radiosurgery centers globally, with particular growth in regions such as Asia-Pacific and Latin America.

Furthermore, as the global burden of cancer continues to rise, particularly with the increasing incidence of brain metastases, the need for advanced radiosurgical tools like Gamma Knife is expected to grow. These regulatory and healthcare trends are shaping the market by ensuring that Gamma Knife remains a safe, effective, and financially viable option for treating complex brain conditions.

What Are the Key Drivers Behind the Growth of the Gamma Knife Market?

The growth in the Gamma Knife market is driven by several key factors, including the increasing incidence of brain disorders, advancements in radiosurgical technology, and the growing demand for minimally invasive treatment options. One of the primary drivers is the rising prevalence of brain tumors, vascular malformations, and neurological disorders, which has increased the need for precise and effective treatment modalities. Gamma Knife radiosurgery is widely recognized for its ability to treat these conditions with minimal risk, making it a preferred choice for patients who are not candidates for traditional surgery. Another significant driver is the advancement in imaging and radiation technologies, which have enhanced the accuracy and safety of Gamma Knife treatments. These innovations allow healthcare providers to treat more complex cases, improve patient outcomes, and reduce side effects. Additionally, the aging global population is contributing to the growth of the Gamma Knife market, as elderly patients are often at higher risk for brain conditions and are more likely to seek non-invasive treatments.

The demand for outpatient procedures is also rising, as patients and healthcare providers seek treatments that offer faster recovery times and fewer complications. Gamma Knife treatments typically require no overnight hospital stay, making them an appealing option in outpatient settings. The growing availability of Gamma Knife centers worldwide, particularly in emerging markets, is further driving the expansion of the market as more healthcare providers invest in this cutting-edge technology. Together, these factors-rising demand for non-invasive treatments, technological advancements, and the increasing burden of neurological diseases-are driving robust growth in the global Gamma Knife market, positioning it as a key tool in the future of neurosurgery.

SCOPE OF STUDY:

The report analyzes the Gamma Knife market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders, Ocular Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â